

**MACROMOLECULAR 4-AMINOQUINOLINE
COMPOUNDS AS POTENTIAL
ANTIMALARIAL DRUGS**

Aderibigbe, Blessing

A thesis submitted to the faculty of Science, University of the Witwatersrand, in fulfilment of the requirements for the degree of Doctor of Philosophy of Science.

September 2010

DECLARATION

I declare that the work presented in this thesis was carried out by me under the supervision of Prof. E. W. Neuse. It is being submitted in fulfilment for the degree of Doctor of Philosophy of Science in the University of Witwatersrand, Johannesburg, South Africa. It has not been submitted before for any degree of examination in any other University.

Aderibigbe, Blessing

_____ day of _____, 2010

DEDICATION

This thesis is dedicated to the Almighty God, who made this programme a success.

ACKNOWLEDGMENTS

I express my sincere gratitude to the following people for their contribution in the accomplishment of this thesis.

Prof. E. W. Neuse, my supervisor, for his guidance and help throughout the programme.

Prof. P. J. Smith, Associate professor of Pharmacology, University of Cape Town, and his research team members for all the cell culture testing.

Mr. Richard Mampa, for all the ^1H NMR spectroscopy.

All my colleagues, Elie, Bavon, Jacob, Jacques, Alain for their encouragement.

My parent for their financial support, prayers and encouragement.

My husband and daughter for their support and help.

LIST OF ABBREVIATIONS

AEE- 2(2-aminoethoxy)ethanol
AEM- 4(2-aminoethyl)morpholine
AEP- 1(2-aminoethyl)piperazine
AGM- aminoglutethimide
APD- (\pm)-3-amino-1,2-propanediol
DCC- Dicyclohexylcarbodiimide
DCM- Dichloromethane
DDT- Dichlorodiphenyltrichloroethane
DEEA- 2-Diethylaminoethylamine
DEP-3-Diethylamino-1-propylamine
DET- Diethylenetriamine
DME- 2-Dimethylaminoethylamine
DMF- N,N-Dimethylformamide
DMP- 3-Dimethylamino-1-propylamine
DNA- Deoxyribonucleic acid
DOX- Doxorubicin (DOX)
DOXP- 1-Deoxy-D-xylulose-5-phosphate
EA- Ethanolamine
EDA- Ethylenediamine
EDDA- 2,2¹-(Ethylenedioxy)diethylamine
Et₂O- Diethyl ether
EtOAc- Ethyl acetate
FabI- Enoyl-acyl-carrier protein reductase
FabH- β -ketoacyl-acyl-carrier protein synthase
G6PD- Glucose-6-phosphate dehydrogenase
HBTU- 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
HPMA- *N*-(2-hydroxypropyl)metacrylate polymers
MBA- Methylenebisacrylamide
MRP- Multiple resistance associated proteins

NMR- Nuclear magnetic resonance

N,N-Diethyldiethylenetriamine

PDA- 1,3-Diaminopropane

PSI- Polysuccinimide

RNA- Ribonucleic acid

TEA- Triethylamine

TRIS- Tris(2-aminoethyl)amine

WHO- World Health Organization

ABSTRACT

4-Aminoquinolines have a long and successful history as antimalarials as they have provided a number of useful antimalarials. *P. falciparum*, a causative organism of the most deadly form of human malaria, is generally slow to develop resistance to these drugs. 4-Aminoquinoline derivatives appear to bind to nucleoproteins and interfere with protein synthesis in susceptible organisms; the drugs intercalate readily into double-stranded DNA and inhibit both DNA and RNA polymerase. In addition, 4-aminoquinolines are found to concentrate in parasites' digestive vacuoles, thereby increasing the pH of the vacuoles, and thus interfere with the parasites' ability to metabolize. 4-Aminoquinolines on the other hand have raised considerable interest because of their anti-carcinogenic properties and their ability to inhibit tumor development and presently are being used in combination therapy with anti-cancer drugs to inhibit development of drug resistance in cancer cells caused by anti-cancer drugs. 8-Aminoquinoline mechanism is quite different from that of 4-aminoquinoline in that the 8-aminoquinolines are converted in the liver to an active quinone metabolite creating oxygen free radicals that interfere with the plasmodial electron chain transport chain during respiration.

Anti-cancer drugs are often toxic when delivered straight, but the bioreversible drug conjugation of anticancer drugs to water-soluble macromolecular carriers has proved to enhance the therapeutic effectiveness of anticancer drugs. Following facilitated pharmacokinetics pathways, the conjugates, acting as prodrugs, will release the active drug species in the transformed target cells and their designs are geared towards reducing pharmacological barriers of toxicity, drug resistance and poor bioavailability encountered with currently used anti-cancer drugs. In order to demonstrate the multidrug binding capacity of polyaspartamide, the co-conjugation of 4- and 8-aminoquinoline derivatives with anti-cancer agents was achieved, and the co-conjugates are expected to serve as resistance-reducing agents.

This present project aimed at the anchoring of 4-aminoquinoline to various amine functionalized polymeric carriers, and selected macromolecular 4-aminoquinoline compounds were screened for *in vitro* antiplasmodial activity.

TABLE OF CONTENTS

DECLARATION.....	ii
DEDICATION.....	iii
ACKNOWLEDGEMENTS.....	iv
LIST OF ABBREVIATIONS.....	v
ABSTRACT.....	vii
CHAPTER 1: INTRODUCTION.....	1
1.1 Polymer-drug conjugation technique.....	2
1.2 Aims of research.....	3
1.3 References cited in chapter 1.....	5
CHAPTER 2: BACKGROUND AND LITERATURE REVIEW.....	7
2.1 Malaria control and prevention.....	7
2.2 The life cycle of malaria parasite.....	8
2.3 Symptoms of malaria.....	10
2.4 Evolutionary pressure of malaria on human genes.....	10
2.5 Currently used antimalarials.....	11
2.5.1 Chloroquine.....	12
2.5.2 Quinine.....	13
2.5.3 Mefloquine.....	14
2.5.4 Primaquine.....	15
2.5.5 Amodiaquine.....	15
2.5.6 Pyrimethamine.....	16
2.5.7 Proguanil.....	16
2.5.8 Sulphadoxine.....	17
2.5.9 Atovaquone.....	17
2.5.10 Hydrochloroquine.....	18
2.5.11 Doxycycline.....	18
2.5.12 Halofantrin.....	19

2.5.13 Artemisinin and derivatives.....	19
2.6 Resistance to antimalarials.....	22
2.7 Combination therapy for antimalarial chemotherapy.....	23
2.7.1 Non-artemisinin based combinations.....	23
2.7.2 Artemisinin based combinations.....	23
2.8 Antimalarial compounds target location.....	23
2.8.1 Cytosolic targets.....	25
2.8.2 Parasite membrane targets.....	25
2.8.3 Food vacuole targets.....	25
2.8.4 Mithochondrial targets.....	26
2.8.5 Apicoplast targets.....	26
2.9 Resistance to 4-aminoquinoline.....	26
2.10 Resistance to 8-aminoquinoline.....	27
2.11 Literature review on 4-aminoquinolines.....	27
2.11.1 Mechanism of action of chloroquine.....	28
2.12 Synthesis of 4-aminoquinolines.....	28
2.13 The use of antimalarials to reduce resistance of anticancer drugs.....	31
2.14 Pharmacokinetics of antimalarials.....	32
2.15 Literature review of anticancer drugs.....	32
2.15.1 Classification.....	33
2.15.2 Cancer treatment options.....	33
2.16 Types of chemotherapeutic drugs.....	34
2.17 Example of commonly used anticancer agents.....	35
2.17.1 Gemcitabine.....	35
2.17.2 Fluorouracil.....	36
2.17.3 Carboplatin.....	36
2.17.4 Methotrexate.....	37
2.17.5 Ferrocene.....	37
2.17.6 Doxorubicin.....	38
2.18 Causes of resistance to anticancer drugs.....	38
2.19 Pharmacological deficiencies in currently used anticancer drugs.....	39

2.20 Polymer-drug conjugation concept.....	40
2.21 Macromolecular carrier systems.....	41
2.21.1 α,β -DL polyaspartamides.....	42
2.21.2 Polyamidoamines.....	43
2.21.3 <i>N</i> -(2-hydroxypropyl)methacrylamides (HPMA).....	44
2.22 Pharmacokinetics pathway of polymer-drug conjugate.....	45
2.23 Polymer conjugation of anticancer drugs.....	46
2.24 Novel approach of polymer-drug conjugation of anticancer drugs.....	46
2.25 Bio-evaluation in cell culture tests: Preliminary results.....	50
2.26 References cited in chapter 2.....	55

CHAPTER 3: RESULTS AND DISCUSSION.....66

3.1 Amination reactions of 4,7-dichloroquinoline.....	66
3.1.1 <i>N</i> -(7-Chloroquinolin-4-yl)propane-1,3-diamine (PDA.Q).....	68
3.1.2 <i>N</i> -(7-Chloro-4-quinolyl)-tris(2-aminoethyl)amine (TRIS.Q).....	68
3.1.3 <i>N</i> -(2-(2-Diethylamino)ethylamine)-7-chloroquinoline-4-amine (NN.Q).....	69
3.1.4 <i>N</i> -(2-(2-Aminoethylamino)ethyl)-7-chloroquinoline-4-amine (DET.Q).....	70
3.2 Liberation of free base primaquine.....	70
3.3 4-Aminoquinoline conjugates (PDA.Q).....	71
3.3.1 PSI. DMP(90) PDA.Q (10).....	71
3.3.2 PSI. DME (90) PDA.Q (10).....	73
3.3.3 PSI. APM (90) PDA.Q (10).....	74
3.3.4 PSI. AEM (90) PDA.Q (10).....	75
3.3.5 PSI. DEP (90) PDA.Q (10).....	76
3.3.6 PSI. DEEA (90) PDA.Q (10).....	77
3.3.7 PSI. EA (90) PDA.Q (10).....	78
3.4 8-Aminoquinoline conjugates.....	79
3.4.1 PSI. DME (90) PRIMAQUINE (10).....	80
3.4.2 PSI DMP (90) PRIMAQUINE (10).....	81
3.4.3 PSI. DEP (90) PRIMAQUINE (10).....	82
3.4.4 PSI.DEEA (90) PRIMAQUINE (10).....	83

3.4.5 PSI. APM (90) PRIMAQUINE (10).....	84
3.5 PSI. APM (90) DET.Q (10).....	85
3.6 PSI. APM (90) TRIS.Q (10).....	86
3.7 Synthesis of co-polymers with PDA drug binding site.....	87
3.8 Synthesis of co-polymers with APD drug binding site.....	90
3.9 Synthesis of co-polymers with EDA drug binding site.....	95
3.10 Co-polymers with primaquine.....	98
3.11 Synthesis of polyamidoamines containing PDA.Q.....	100
3.12 Polymeric carrier with two drug systems.....	102
3.12.1 PSI. APM (80) PRIMAQUINE (10) APD (10). Pt.....	103
3.12.2 PSI. AEM (80) PDA.Q (10) APD (10). Pt.....	103
3.12.3 PSI. DMP (80) PDA.Q (10) PDA (10) Ferrocene.....	104
3.13 <i>IN VITRO</i> antiplasmodial activity of some homopolymer with 4- and 8- aminoquinoline compounds.....	105
3.13.1 Methodology.....	105
3.13.2 Results.....	105
3.14 References used in chapter 3.....	107

CHAPTER 4: CONCLUSION AND FUTURE WORK.....108

4.1 Summary.....	108
4.1.1 Homopolymers with PDA.Q.....	108
4.1.2 Homopolymers with 8-aminoquinoline.....	108
4.1.3 Homopolymers with DET.Q and TRIS.Q.....	109
4.1.4 Co-polymers with PDA.Q and APD drug binding site.....	109
4.1.5 Co-polymers with PDA.Q and EDA drug binding site.....	109
4.1.6 Co-polymers with Primaquine.....	109
4.2 Future work.....	109

CHAPTER 5: EXPERIMENTAL.....111

5.1 General procedures.....	111
5.2 Reagents, reactants and solvents.....	111

5.3 Experimental procedures.....	112
5.3.1 Synthesis of 4-aminoquinolines.....	112
5.3.1.1 <i>N'</i> -(7-Chloroquinolin-4-yl-)propane-1,3-diamine (PDA.Q).....	112
5.3.1.2 N-(2-(2-(diethylamino)ethylamine)ethyl)-7-chloroquinoline-4-amine (NNQ).	113
5.3.1.3 N-(2-(2-Aminoethylamino)ethyl)-7-chloroquinoline-4-amine (DET.Q).....	114
5.3.1.4 TRIS.Q.....	114
5.3.2 Preparation of poly- $\alpha\beta$ -DL-succinimide (PSI).....	115
5.4 Synthesis of homopolymers with PDA.Q.....	115
5.4.1 PSI. DMP (90) PDA.Q (10).....	115
5.4.2 PSI. DME (90) PDA.Q (10).....	116
5.4.3 PSI. DEEA (90) PDA.Q (10).....	117
5.4.4 PSI. DEP (90) PDA.Q (10).....	118
5.4.5 PSI. EA (90) PDA.Q (10).....	119
5.4.6 PSI. APM (90) PDA.Q (10).....	120
5.4.7 PSI AEM (90) PDA.Q (10).....	121
5.5 Synthesis of homopolymers with primaquine.....	122
5.5.1 PSI. DME (90) PRIMAQUINE.....	122
5.5.2 PSI. DMP (90) PRIMAQUINE.....	123
5.5.3 PSI. DEP (90) PRIMAQUINE.....	124
5.5.4 PSI. APM (90) PRIMAQUINE.....	125
5.5.5 PSI. DEEA (90) PRIMAQUINE.....	126
5.6 Synthesis of homopolymers with DET.Q (PSI. APM (90) DET.Q (10)).....	127
5.7 Homopolymers with TRIS.Q (PSI. APM (90) TRIS.Q (10)).....	128
5.8 Synthesis of co-polymers for anticancer drug anchoring.....	129
5.8.1 PSI. AEM (80) PDA.Q (10) PDA (10).....	129
5.8.2 PSI. APM (80) PDA.Q (10) PDA (10).....	130
5.8.3 PSI. EA (80) PDA.Q (10) PDA (10).....	131
5.8.4 PSI. DMP (80) PDA.Q (10) PDA (10).....	132
5.8.5 PSILAPM (80) PDA.Q (10) APD (10).....	133
5.8.6 PSI. AEM (80) PDA.Q (10) APD (10).....	134

5.8.7 PSI. DEP (80) PDA.Q (10) APD (10).....	135
5.8.8 PSI. EA (80) PDA.Q (10) APD (10).....	136
5.8.9 PSI. DEEA (80) PDA.Q (10) APD (10).....	137
5.8.10 PSI. DME (80) PDA.Q (10) APD (10).....	138
5.8.11 PSI. DMP (80) PDA.Q (10) APD (10).....	139
5.8.12 PSIAEP (80) PDA.Q (10) APD (10).....	140
5.8.13 PSI. APM (80) PDA.Q (10) EDA (10).....	141
5.8.14 PSI. AEM (80) PDA.Q (10) EDA (10).....	142
5.8.15 PSI. DEEA (80) PDA.Q (10) EDA (10).....	143
5.8.16 PSI. DME (80) PDA.Q (10) EDA (10).....	144
5.8.17 PSI. DMP (80) PDA.Q (10) EDA (10).....	145
5.8.18 PSI. APM (80) PRIMAQUINE (10) APD (10).....	146
5.8.19 MBA.APD.PDA.Q.APD (3:1:1:1).....	147
5.9 Polymeric two drug co-conjugate.....	148
5.9.1 PSI. APM (80) PRIMAQUINE (10) APD (10). Pt.....	148
5.9.2 PSI. AEM (80) PDA.Q (10) APD (10) . Pt.....	148
5.9.3 PSI. DMP (80) PDA.Q (10) EDA (10). Ferrocene.....	149
5.10 References used in chapter 4.....	150

APPENDIX I ('H NMR SPECTRA).....151

APPENDIX II.....152

(Dose-response curves of test samples against the CQS D10 strain of *P. falciparum*)